Adagio Medical Holdings, Inc. (ADGM) intrinsic value & 10-year financials
Adagio Medical Holdings, Inc. (ADGM) has a Graham intrinsic value of $249.06 per share. At $0.10 on Oct 17, 2026, the stock trades 100% below that value. Over the last 4 fiscal years revenue shrank 99.8% a year to $0, with an average return on invested capital of -53.0%.
- Graham intrinsic value
- $249.06
- Share price (Oct 17, 2026)
- $0.10
- Price vs Graham value
- 100% below
- Market cap
- $1.6M
- Revenue (FY2025)
- $0
- Revenue growth (4-yr CAGR)
- -99.8%
- ROIC (10-yr avg)
- -53.0%
- Free cash flow (FY2025)
- -$19.4M
ADGM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$25.1M | -$1.51 | -$19.4M | — | -135.3% |
| FY2024 | $465 | — | — | — | — | — |
| FY2023 | $300.0K | -$36.6M | -$48.16 | -$26.0M | -9314.0% | 29.4% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Adagio Medical Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Adagio Medical Holdings, Inc. has historically struggled to out-earn its cost of capital, averaging just -53.0% ROIC.
Adagio Medical Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Adagio Medical Holdings, Inc. is modeled at -99.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $249.06 per share.